Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC.

Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC.
Clin Cancer Res. 2019 Jan 07;:
Authors: Pinyol R, Sia D, Llovet JM
Abstract
Next generation sequencing has provided information on actionable targets and biomarkers of response in oncology. In HCC, Wnt/CTNNB1 mutations characterize the immune excluded class (cold tumors) and might represent the biomarkers predicting resistance to immune checkpoint inhibitors. Large-scale validation of this data is needed to customize immunotherapy in advanced HCC.
PMID: 30617138 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 7, 2019 Category: Cancer & Oncology Authors: Pinyol R, Sia D, Llovet JM Tags: Clin Cancer Res Source Type: research